Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
May modify the assembly dynamics of microtubules, such that microtubules are slightly longer, but more dynamic (By similarity). Additionally we are shipping EML4 Proteins (4) and many more products for this protein.
Showing 10 out of 35 products:
Human Polyclonal EML4 Primary Antibody for ICC, IF - ABIN4307859
Preusser, Berghoff, Ilhan-Mutlu, Magerle, Dinhof, Widhalm, Dieckmann, Marosi, Wöhrer, Hackl, Zöchbauer-Müller, von Deimling, Schoppmann, Zielinski, Streubel, Birner: ALK gene translocations and amplifications in brain metastases of non-small cell lung cancer. in Lung cancer (Amsterdam, Netherlands) 2013
Show all 3 Pubmed References
Human Monoclonal EML4 Primary Antibody for IHC (p), ELISA - ABIN565390
Radtke, Rezaie, Kugler, Zabel, Schultz, Vollmer, Goldmann, Lang: Expression analysis of EML4 in normal lung tissue and non-small cell lung cancer (NSCLC) in the absence and presence of chemotherapeutics. in Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie 2010
Coupling an EML4-ALK (show ALK Antibodies)-centric interactome with RNA interference identifies sensitizers to ALK (show ALK Antibodies) inhibitors
identified EML4-ALK (show ALK Antibodies) gene rearrangement in expanded circulating tumor cells from a patient with ALK (show ALK Antibodies)-positive lung adenocarcinoma
Knockdown of SMYD2 (show SMYD2 Antibodies) as well as treatment with a SMYD2 (show SMYD2 Antibodies) inhibitor in two NSCLC cell lines with an EML4-ALK (show ALK Antibodies) gene significantly attenuated the phosphorylation levels of the EML4-ALK (show ALK Antibodies) protein.
The EML4-ALK (show ALK Antibodies)-mediated upregulation of HIF1alpha (show HIF1A Antibodies), HK2 (show HK2 Antibodies) and glycolytic metabolism was also highly active in vivo as demonstrated by fluorodeoxyglucose-positron emission tomography imaging of xenografts grown from EML4-ALK (show ALK Antibodies)-positive NSCLC cells.
We assessed the prevalence of EML4-ALK (show ALK Antibodies) rearrangement gene measured by immunohistochemistry in an unselected population-based consecutive cohort of patients with adenocarcinoma of the lung (ACL (show ACLY Antibodies)), and the correlation with smoking history, thyroid transcription factor 1 (TTF1 (show NKX2-1 Antibodies)), gender and age
Our findings show that group EML4-ALK (show ALK Antibodies) variants 3a/b in non-small cell lung cancer may be a major source of ALK (show ALK Antibodies) inhibitor resistance in the clinic.
EML4-ALK (show ALK Antibodies) rearrangement detection in malignant pleural effusions is a complementary method for EML4-ALK (show ALK Antibodies) detection. VETANA and qRT-PCR are more appropriate for MPE detection. EML4-ALK (show ALK Antibodies) rearrangement in pleural effusions has a predictive value for treatment.
EML4-ALK (show ALK Antibodies)-positive lung cancer is often highly progressive.
case report in which the EML4-ALK (show ALK Antibodies) fusion gene was identified as a second primary lung cancer after surgically resecting EGFR (show EGFR Antibodies) mutation-positive adenocarcinoma
79 (69%) were negative for echinoderm microtubule-associated protein like 4 (EML4)-ALK (show ALK Antibodies) translocation, nine (8%) were positive and 27 (23%) were unevaluable.
May modify the assembly dynamics of microtubules, such that microtubules are slightly longer, but more dynamic (By similarity).
echinoderm microtubule-associated protein-like 4
, echinoderm microtubule associated protein like 4
, echinoderm microtubule-associated protein-like 4-like
, restrictedly overexpressed proliferation-associated protein
, ropp 120